Corinfar, 10 mg, extended-release film-coated tablets, 50 pcs.
During the treatment period it is necessary to refrain from taking ethanol.
It is recommended to stop treatment with the drug gradually.
It should be borne in mind that angina pectoris may occur at the beginning of treatment, especially after recent abrupt withdrawal of beta-blockers (the latter should be withdrawn gradually).
The simultaneous administration of beta-blockers must be carried out under conditions of careful medical supervision, as this may cause an excessive decrease in blood pressure, and in some cases, aggravation of symptoms of heart failure.
In case of severe heart failure, the drug is dosed with great caution.
Diagnostic criteria for prescribing the drug for vasospastic angina are: a classic clinical picture, accompanied by an increase in the ST segment, the occurrence of ergonovine-induced angina or coronary artery spasm, detection of coronary spasm during angiography or identification of an angiospastic component without confirmation (for example, with a different voltage threshold or with unstable angina, when data ECGs indicate transient vasospasm).
For patients with severe obstructive cardiomyopathy, there is a risk of increased frequency, severity and duration of angina attacks after taking nifedipine; in this case, discontinuation of the drug is necessary.
In patients with irreversible renal failure who are on hemodialysis, have high blood pressure and a reduced total blood volume, the drug should be used with caution, as a sharp drop in blood pressure is possible. Patients with impaired liver function are closely monitored; if necessary, reduce the dose of the drug and/or use other dosage forms of nifedipine.
If surgery under general anesthesia is necessary, the anesthesiologist must be informed about the patient's treatment with nifedipine.
During in vitro fertilization, in some cases, BMCC cause changes in the head part of the sperm, which can lead to dysfunction of the sperm. In cases in which repeated in vitro fertilization has not been carried out for an unclear reason, the use of BMCC, including nifedipine, can be considered a possible reason for failure.
During treatment, it is possible to obtain a false positive result from the direct Coombs test and laboratory tests for antinuclear antibodies. In the spectrophotometric determination of vanillylmandelic acid in urine, nifedipine may cause a falsely elevated result, however, nifedipine does not affect the results of tests performed using high-performance liquid chromatography.
Caution should be exercised during simultaneous treatment with nifedipine, disopyramide and flecainamide due to a possible increase in inotropic effect.
Impact on the ability to drive a car and other mechanisms
During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
CORINTHAR RETARD
Interaction
- With simultaneous use of other antihypertensive drugs, as well as tricyclic antidepressants, nitrates, cimetidine, inhalational anesthetics, diuretics, the hypotensive effect of nifedipine may be enhanced.
- Blockers of “slow” calcium channels can further enhance the negative inotropic effect of antiarrhythmics such as amiodarone and quinidine.
— When combining nifedipine with nitrates, tachycardia increases.
— Diltiazem inhibits the metabolism of nifedipine in the body, which may require a reduction in the dose of nifedipine when these drugs are prescribed simultaneously.
- Reduces the concentration of quinidine in blood plasma.
— Increases the concentration of digoxin and theophylline in the blood plasma.
— Rifampicin accelerates the metabolism of nifedipine; co-administration is not recommended.
- When administered concomitantly with cephalosporins (for example, cefixime), the bioavailability of cephalosporins may increase by 70%.
- Sympathomimetics, non-steroidal anti-inflammatory drugs (suppression of prostaglandin synthesis in the kidneys and retention of sodium ions and fluid in the body), estrogens (fluid retention in the body) reduce the hypotensive effect.
- Nifedipine can displace drugs with a high degree of binding from proteins (including indirect anticoagulants - derivatives of coumarin and indandione, anticonvulsants, non-steroidal anti-inflammatory drugs, quinine, salicylates, sulfinpyrazone), as a result of which their concentration in the blood plasma may increase .
- Nifedipine inhibits the metabolism of prazosin and other alpha-blockers, which can lead to an increased hypotensive effect.
— If necessary, reduce the dose of vincristine, because Nifedipine inhibits its elimination from the body, which may cause increased side effects.
— Lithium preparations can increase toxic effects (nausea, vomiting, diarrhea, ataxia, tremor, tinnitus).
- With the simultaneous administration of procainamide, quinidine and other drugs that cause prolongation of the QT interval, the risk of significant prolongation of the QT interval increases.
— Grapefruit juice inhibits the metabolism of nifedipine in the body, so it is contraindicated during treatment with nifedipine.
- Nifedipine is metabolized by the cytochrome P450 3A system, therefore, the simultaneous use of drugs that inhibit this system can lead to interaction between this drug and nifedipine: for example, macrolides, antiviral drugs (for example, amprenavir, indinavir, nelfinavir, ritonavir or saquinavir) ; antifungals of the azole group (ketoconazole, itraconazole or fluconazole) cause an increase in the concentration of nifedipine in the blood plasma.
— Taking into account the experience with the use of nimodipine BMCC, similar interactions with nifedipine cannot be excluded: carbamazepine, phenobarbital can cause a decrease in the concentration of nifedipine in the blood plasma; and valproic acid increases the concentration of nifedipine in the blood plasma.
CORINPHAR extended-release film-coated tablets 10 mg No. 100
With the simultaneous use of other antihypertensive drugs, as well as tricyclic antidepressants, nitrates, cimetidine, inhalational anesthetics, diuretics, the hypotensive effect of nifedipine may be enhanced. BMCCs may further enhance the negative inotropic effects of antiarrhythmic drugs such as amiodarone and quinidine. When nifedipine is combined with nitrates, tachycardia increases. Diltiazem inhibits the metabolism of nifedipine in the body, which may require a reduction in the dose of nifedipine when these drugs are prescribed simultaneously. Reduces the concentration of quinidine in blood plasma. Increases the concentration of digoxin and theophylline in the blood plasma. Rifampicin accelerates the metabolism of nifedipine; co-administration is not recommended. When administered simultaneously with cephalosporins (for example, cefixime), the concentration of cephalosporins in the blood may increase. Sympathomimetics, NSAIDs (suppression of PG synthesis in the kidneys and retention of sodium ions and fluid in the body), estrogens (fluid retention in the body) reduce the hypotensive effect. Nifedipine can displace drugs with a high degree of binding from proteins (including indirect anticoagulants - coumarin and indanedione derivatives, anticonvulsants, NSAIDs, quinine, salicylates, sulfinpyrazone), as a result of which their concentration in the blood plasma may increase. Nifedipine inhibits the metabolism of prazosin and other alpha-blockers, which can lead to increased hypotensive effect. If necessary, the dose of vincristine is reduced, because Nifedipine inhibits its elimination from the body, which may cause increased side effects. Lithium preparations may enhance toxic effects (nausea, vomiting, diarrhea, ataxia, tremor, tinnitus). When procainamide, quinidine and other drugs known to prolong the QT interval are co-administered, the risk of significant prolongation of the QT interval increases. Grapefruit juice inhibits the metabolism of nifedipine in the body and is therefore contraindicated during treatment with nifedipine. Nifedipine is metabolized by the cytochrome P450 3A system, and therefore the simultaneous use of drugs that inhibit this system can lead to interaction between this drug and nifedipine: for example, macrolides, antiviral drugs (for example, amprenavir, indinavir, nelfinavir, ritonavir or saquinavir); antifungals of the azole group (ketoconazole, itraconazole or fluconazole) cause an increase in the concentration of nifedipine in the blood plasma. Taking into account the experience with the use of nimodipine BMCC, similar interactions with nifedipine cannot be excluded: carbamazepine, phenobarbital can cause a decrease in the concentration of nifedipine in the blood plasma; and valproic acid increases the concentration of nifedipine in the blood plasma.
Corinfar®
During the treatment period it is necessary to refrain from taking ethanol. It is recommended to stop treatment with the drug gradually.
It should be borne in mind that angina pectoris may occur at the beginning of treatment, especially after recent abrupt withdrawal of beta-blockers (the latter should be withdrawn gradually).
The simultaneous administration of beta-blockers must be carried out under conditions of careful medical supervision, as this may cause an excessive decrease in blood pressure, and in some cases, aggravation of symptoms of heart failure.
In case of severe heart failure, the drug is dosed with great caution.
Diagnostic criteria for prescribing the drug for vasospastic angina are: a classic clinical picture, accompanied by an increase in the ST segment, the occurrence of ergonovine-induced angina or coronary artery spasm, detection of coronary spasm during angiography or identification of an angiospastic component without confirmation (for example, with a different voltage threshold or with unstable angina, when ECG data indicate transient vasospasm).
For patients with severe obstructive cardiomyopathy, there is a risk of increased frequency, severity and duration of angina attacks after taking nifedipine; in this case, discontinuation of the drug is necessary.
In patients with irreversible renal failure who are on hemodialysis, have high blood pressure and reduced blood volume, the drug should be used with caution, because a sharp drop in blood pressure is possible. Patients with impaired liver function are closely monitored; if necessary, reduce the dose of the drug and/or use other dosage forms of nifedipine.
If surgical intervention under anesthesia is necessary, it is necessary to inform the anesthesiologist about the patient's treatment with nifedipine.
During in vitro fertilization, in some cases, BMCC caused changes in the head part of the sperm, which can lead to dysfunction of the sperm. In cases in which repeated in vitro fertilization has not been carried out for an unclear reason, the use of BMCC, including nifedipine, can be considered a possible reason for failure.
During treatment, it is possible to obtain a false-positive result from the direct Coombs test and laboratory tests for antinuclear antibodies.
In the spectophotometric determination of vanillyl-mandelic acid in urine, nifedipine may cause a falsely high result, however, nifedipine does not affect the results of tests carried out using HPLC.
Caution should be exercised during simultaneous treatment with nifedipine, disopyramide and flecainamide due to a possible increase in inotropic effect.
Impact on the ability to drive a car and other mechanisms
During the treatment period, patients must be careful when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
